Bold New Bioengineering Methods and Approaches for Heart, Lung, Blood and Sleep Disorders and Diseases (R21)

Funding Agency:
National Institutes of Health

The purpose of this Funding Opportunity Announcement (FOA) is to encourage basic, translational, and clinical proof-of-concept research projects that are needed for the advancement of bioengineering approaches for heart, lung, blood and sleep diseases.


  • Letter of Intent Due Date(s): 30 days before the application due date
  • Application Due Date(s): New Dates October 13, 2016; January 10, 2017; May 10, 2017; January 10, 2018; May 10, 2018
  • AIDS Due Dates: Jan. 7, May 7, Sep. 7

​RFA-HL-17-015 Expiration Date New Date September 8, 2018 per issuance of NOT-HL-17-567. (Original Expiration Date: May 11, 2019)

Agency Website



Amount Description

Direct costs are limited to $275,000 over a two-year period, with no more than $150,000 in direct costs allowed in any single year.  

Funding Type





Engineering and Physical Sciences
Environmental & Life Sciences
Medical - Basic Science
Medical - Clinical Science
Medical - Translational

External Deadline

May 10, 2018